BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buensalido JAL, Chandrasekar PH. Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab. Expert Review of Anti-infective Therapy 2013;12:151-4. [DOI: 10.1586/14787210.2014.870473] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nat Rev Dis Primers 2017;3:16096. [PMID: 28102226 DOI: 10.1038/nrdp.2016.96] [Cited by in Crossref: 174] [Cited by in F6Publishing: 156] [Article Influence: 34.8] [Reference Citation Analysis]
2 Junus K, Aguilar M, Patel P, Irwin D, Yee S, Liu B, Bhuket T, Wong RJ. Improvements in hepatitis B virus screening before rituximab therapy: A community-based, safety-net hospital experience. Cancer 2017;123:650-6. [PMID: 27696389 DOI: 10.1002/cncr.30381] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kusumoto S, Arcaini L, Hong X, Jin J, Kim WS, Kwong YL, Peters MG, Tanaka Y, Zelenetz AD, Kuriki H, Fingerle-Rowson G, Nielsen T, Ueda E, Piper-Lepoutre H, Sellam G, Tobinai K. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood. 2019;133:137-146. [PMID: 30341058 DOI: 10.1182/blood-2018-04-848044] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]
4 Sandherr M, Hentrich M, von Lilienfeld-Toal M, Massenkeil G, Neumann S, Penack O, Biehl L, Cornely OA. Antiviral prophylaxis in patients with solid tumours and haematological malignancies--update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). Ann Hematol 2015;94:1441-50. [PMID: 26193852 DOI: 10.1007/s00277-015-2447-3] [Cited by in Crossref: 65] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
5 Davis JS, Ferreira D, Paige E, Gedye C, Boyle M. Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. Clin Microbiol Rev 2020;33:e00035-19. [PMID: 32522746 DOI: 10.1128/CMR.00035-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]